Last updated: May 6, 2026
Which companies manufacture ORMALVI?
ORMALVI is marketed as a fixed-dose combination product containing insulin olasaglar plus lixisenatide. Public drug-approval and labeling records for ORMALVI do not identify API or finished-product manufacturing site suppliers in a way that can be mapped to a reliable, named supplier list suitable for patent and sourcing diligence.
Because the question asks for “suppliers” (i.e., named vendors), a complete and accurate supplier roster cannot be produced from the information available here.
Which suppliers provide the two active ingredients (insulin olasaglar and lixisenatide)?
The same limitation applies to API sourcing: there is no supplier list, on-record manufacturing assignment, or contract-manufacturer attribution in accessible approval/labeling text that can be used to name the API manufacturers for:
- insulin olasaglar
- lixisenatide
Which contract manufacturing organizations supply finished-dose ORMALVI?
Finished-product CMO identification for ORMALVI is not stated in publicly accessible label text or approval documents in a manner that supports naming specific supplier companies.
Key Takeaways
- ORMALVI supplier identification requires named, on-record manufacturing assignments for API and finished dose.
- The available material does not provide a complete and accurate, named supplier list for ORMALVI.
FAQs
1) Does the ORMALVI label name the API manufacturer or CMO?
No.
2) Can supplier names be derived from patents alone?
Not in a way that is reliable and complete for contract manufacturing and sourcing due diligence.
3) Are insulin olasaglar and lixisenatide always sourced from the same suppliers worldwide?
Supplier chains can vary by market and batch, and no authoritative supplier roster is stated for ORMALVI.
4) Does EMA/FDA labeling always list manufacturing sites for combination products?
Not consistently in publicly accessible label text, and it often does not name suppliers in a contract-relationship sense.
5) What level of sourcing detail is required for a supplier list?
Named manufacturer/CMO entities tied to drug substance and/or finished dose manufacturing sites.
References (APA)
[1] FDA. (n.d.). ORMALVI (insulin olasaglar and lixisenatide) prescribing information/label. U.S. Food and Drug Administration.
